Patients with radioiodine-refractory (RAIR) differentiated thyroid carcinoma (DTC) represent a challenging subgroup of DTC because they are at higher risk of cancer-related death. Multidisciplinary discussions can assess the role and the nature of local treatments, but also determine the optimal timing for first-line antiangiogenic therapy as some of these patients can be followed for several months or years without any treatment. In this review, we will examine the definition of RAIR-DTC, the different treatment options and finally some of the most recent cancer research breakthroughs for RAIR-DTC.
Keywords: Antiangiogenic; Molecular biology; Network; Radioiodine-refractory differentiated thyroid carcinoma; TUTHYREF; Target therapy.
Copyright © 2019 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.